Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE The receptor tyrosine kinase (RTK) MET represents a promising tumor target in a subset of glioblastomas. 28751462 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE MET immunolabelling is a useful predictive tool for MET gene amplification in glioblastoma. 26946354 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma. 28504721 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE Our data provide new insights into the potential application of miR-144-3p in GBM therapy by targeting MET and then inhibiting the downstream signaling. 26250785 2016
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE PV-O glioblastomas were associated with lower expression of VEGFC (p = 0.032) than other periventricular locations, whereas MET overexpression remained exceptional. 26637806 2016
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE PKCδ activated by c-MET enhances infiltration of human glioblastoma cells through NOTCH2 signaling. 26700818 2016
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma. 26381735 2016
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 GeneticVariation disease BEFREE GBM individuals with MET-pathway pairs showed significantly shorter survival times than those with only MET amplification. 24911613 2015
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE We show that the RTKs MET, EGFR, and PDGFR regulate microRNA-134 (miR-134) in GBM. 24440911 2015
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. 25135958 2015
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE In contrast to the classical subtype of primary glioblastoma, the cases studied here were characterized by the absence of EGFR amplification, PTEN loss, and 9p homozygous deletion and overexpression of p53, PDGFRα, and c-MET, suggesting that they can be classified as the proneural or mesenchymal subtype of glioblastoma and benefit from intensive therapy that includes temozolomide. 24457079 2014
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE The MET oncogene in glioblastoma stem cells: implications as a diagnostic marker and a therapeutic target. 23695554 2014
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE This study demonstrated that (18)F-FBPA was predominantly transported by system L in human glioblastoma cells compared to (14)C-MET. 23557719 2014
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE These results suggest that the c-Met/HGF signaling axis is enhanced by ΔEGFR through increased STAT3-dependent HGF expression and that targeting c-Met in Mes GBMs may be an important strategy for therapy. 23359207 2013
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE We also showed that Wnt/β-catenin signaling activities in GBM are directly modulated by the addition of ligand-mediated MET activation or MET inhibition. 23258844 2013
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE MET gain was detected in primary glioblastomas (47%) and secondary glioblastomas (44%), suggesting that this genetic alteration plays a role in the pathogenesis of both glioblastoma subtypes. 22672415 2013
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE We investigated the molecular factors and pathway activation signatures that determine sensitivity to c-MET inhibitors in a panel of glioblastoma and medulloblastoma cells, glioblastoma stem cells, and established cell line-derived xenografts using functional assays, reverse protein microarrays, and in vivo tumor volume measurements, but validation with animal survival analyses remains to be done. 23386689 2013
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. 22203985 2012
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE The MET oncogene is a functional marker of a glioblastoma stem cell subtype. 22738909 2012
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease CTD_human Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. 22162573 2012
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease BEFREE This phenomenon is especially common among tumors with PDGFRA amplification: overall, 43% of PDGFRA-amplified GBM were found to have amplification of EGFR or the hepatocyte growth factor receptor gene (MET) as well. 22323597 2012
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. 22020333 2012
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 Biomarker disease LHGDN PTEN loss amplifies c-Met-induced glioblastoma malignancy. 19190120 2009
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE These results indicate the possible existence of multiple mechanisms of MET activation in glioblastomas and that the activation system of proHGF/SF is important in progression of glioblastomas that express endogenous proHGF/SF and require ligand-dependent MET activation. 16106403 2006
Entrez Id: 4233
Gene Symbol: MET
MET
0.400 AlteredExpression disease BEFREE Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma. 11238734 2001